惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Hugging Face - Blog
Hugging Face - Blog
宝玉的分享
宝玉的分享
G
Google Developers Blog
T
Tailwind CSS Blog
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
V
V2EX
V
Visual Studio Blog
博客园 - Franky
S
SegmentFault 最新的问题
Jina AI
Jina AI
爱范儿
爱范儿
The Cloudflare Blog
酷 壳 – CoolShell
酷 壳 – CoolShell
D
DataBreaches.Net
C
Check Point Blog
月光博客
月光博客
P
Proofpoint News Feed
T
The Blog of Author Tim Ferriss
罗磊的独立博客
H
Hackread – Cybersecurity News, Data Breaches, AI and More
MongoDB | Blog
MongoDB | Blog
The GitHub Blog
The GitHub Blog
Y
Y Combinator Blog
Martin Fowler
Martin Fowler

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Merck KGaA: Bio-Techne Acquisition Improves Quality, But ...
Wolf Report · 2026-06-26 · via All Articles on Seeking Alpha

Summary

  • Merck KGaA delivered a 33% RoR in under three months, driven by strong Q1 results and upgraded guidance.
  • The $11B+ Bio-Techne acquisition enhances vertical integration and recurring revenue and fills workflow gaps, strengthening Merck's three-pillar business model.
  • I raise my price target to €140.4/share, reflecting conservative synergy assumptions and incremental value from the M&A, but see limited risk-adjusted upside at current levels.
  • Given the current valuation, I downgrade Merck KGaA to 'Hold'—the stock is high quality, but not attractively priced for new capital.
  • Looking for more investing ideas like this one? Get them exclusively at Wolf of Value. Learn More »
  • Sitewide Sale 2026: Get 20% Off
Sign and Tower at Merck Headquarters in Darmstadt, Germany

Anne Czichos/iStock Editorial via Getty Images

I cover both Merck (MRK) and Merck KGaA (MKGAF) (which I hereafter will call "Merck", because this article is about the latter), but the latter is more of a focus for me given

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MKGAF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment. I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about. Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company's domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.